ESTRO 2025 - Abstract Book

S796

Clinical - Gynaecology

ESTRO 2025

Conclusion: CRT significantly improved pelvic control in stage III endometrial cancer, particularly for high-risk patients (stage IIIC, high-grade histology, LVSI, and cervical involvement), enhancing both pelvic control and PFS. These findings support CRT as a beneficial adjuvant option for high-risk patients, however, validation in larger cohorts is recommended to confirm generalizability.

Keywords: Endometrial cancer, Radiation therapy, Stage III

References: Matei D, Filiaci V, Randall ME, et al: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 380:2317-2326, 2019 de Boer SM, Powell ME, Mileshkin L, et al: Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. The Lancet Oncology 20:1273-1285, 2019 Chapman BV, Swanick CW, Ning MS, et al: Adjuvant combined-modality therapy for stage IIIC endometrioid and non endometrioid endometrial cancer. Gynecol Oncol 154:22-28, 2019

889

Mini-Oral Whole- versus individualized-uterine radiotherapy in locally advanced cervical cancer: clinical outcome and toxicity Jie Lee 1 , Jhen-Bin Lin 2 , Yu-Jen Chen 3 1 Radiation Oncology, MacKay Memorial Hospital, Taiwan, Taiwan. 2 Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan. 3 Radiation Oncology, MacKay Memorial Hospital, Taipei, Taiwan